Clinical Trial Update: PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating PD-1 combined with dasatinib as third-line therapy for ARID1A-mutant advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DASATINIB (Dasatinib)
• PD-1

Snippet

Sponsor: The Affiliated Hospital of Qingdao University | Conditions: NSCLC Stage IV, ARID1A | Phase 2 | Status: UNKNOWN